BTAI
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc historical holders
total: 1
Oaktree Capital Management BioXcel Therapeutics Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2025 Q2
Howard Marks has been an institutional investor in BioXcel Therapeutics Inc (BTAI) since 2025 Q2. According to 2026 Q1 report, Howard Marks holds 241,188 shares with a market value of roughly $323.19K representing 0.01% of their equity portfolio. The fund/company first acquired BTAI in 2025 Q2, initially purchasing 241,188 shares.
Does Howard Marks still hold BTAI?
Yes, Howard Marks continues to hold BioXcel Therapeutics Inc (BTAI). According to their 2026 Q1 report, they maintain a position of 241,188 shares valued at approximately $323.19K, representing 0.01% of their equity portfolio.
When did Howard Marks first invest in BTAI?
Howard Marks first invested in BioXcel Therapeutics Inc (BTAI) in 2025 Q2 at the reported quarter-end price of $1.81 per share, acquiring 241,188 shares in their initial purchase.
What is Howard Marks's average cost basis for BTAI?
Based on historical transaction data, Howard Marks's estimated cost basis for BioXcel Therapeutics Inc (BTAI) is approximately $1.81 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $1.81
BTAI transactions history by Oaktree Capital Management
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.01%
|
241,188
|
$1.81
|
$436,551
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.